CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myelomaMay 1, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
High-dose MTX-based chemo is well tolerated in older PCNSL patientsApril 24, 2019Lymphoma & Plasma Cell Disorders
Monitoring, early intervention key to CAR T safetyApril 24, 2019Lymphoma & Plasma Cell DisordersHematology
Creating CAR T-cell therapies for T-cell malignanciesApril 16, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphomaApril 5, 2019Lymphoma & Plasma Cell Disorders
ASCO, CCO issue multiple myeloma treatment guidelinesApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZLApril 2, 2019Lymphoma & Plasma Cell Disorders
FDA panel calls for changes to breast implant rupture screeningMarch 27, 2019OncologyLymphoma & Plasma Cell Disorders
FDA panel leans toward more robust breast implant surveillanceMarch 26, 2019Lymphoma & Plasma Cell DisordersOncologyHematology
Oral triplet deemed effective in relapsed/refractory myelomaMarch 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Myeloma risk score has treatment-planning potentialMarch 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Myeloma therapies raise cardiovascular risksMarch 1, 2019Multiple MyelomaHematologyLymphoma & Plasma Cell DisordersOncology
